Microb Pathog:胡桃核果提取物可有效抑制铜绿假单胞菌的活性及生物膜的形成

2018-04-03 MedSci MedSci原创

铜绿假单胞菌是一种机会性病原体,可引起严重的健康问题并产生多种毒力因子,主要归因于生物膜的形成。铜绿假单胞菌生物膜具有较强的耐药性,因此在治疗时需要使用新一代抗生素。多重耐药(MDR)菌株的出现迫使研究人员着手从天然产物或修饰天然化合物筛选生物膜抑制剂。本研究中,研究人员评估了胡桃核果提取物对铜绿假单胞菌临床分离物生物膜形成的抑制作用(抗菌和抗菌膜)。 采用传统生化检测方法收集烧伤、气管和尿液感染

铜绿假单胞菌是一种机会性病原体,可引起严重的健康问题并产生多种毒力因子,主要归因于生物膜的形成。铜绿假单胞菌生物膜具有较强的耐药性,因此在治疗时需要使用新一代抗生素。多重耐药(MDR)菌株的出现迫使研究人员着手从天然产物或修饰天然化合物筛选生物膜抑制剂。本研究中,研究人员评估了胡桃核果提取物对铜绿假单胞菌临床分离物生物膜形成的抑制作用(抗菌和抗菌膜)。

采用传统生化检测方法收集烧伤、气管和尿液感染(确定为铜绿假单胞菌感染)住院患者的样本。使用纸片扩散法进行分离物的抗生素敏感性测试。微量滴定板法用于评估致病菌株生物膜的形成能力。同时使用微量滴定板法测定水和甲醇胡桃叶提取物的抗菌和抗菌膜效果。
 
结果显示,46.7%的铜绿假单胞菌分离株(n = 50)对庆大霉素耐药,100%可形成生物膜。所有分离株均表现出MDR表型。各种浓度的胡桃核果提取物均可明显抑制分离物的生长和生物膜形成。另外,胡桃核叶提取物对浮游生长的抑制活性较好,甲醇提取物对铜绿假单胞菌生物膜的抑制作用更强。

综上所述,该研究结果表明,抗生素耐药菌株与生物膜形成明显相关。胡桃核叶提取物可以提供各种浓度的替代物来控制由铜绿假单胞菌引起的生物膜相关感染。需要进一步的分析来验证这些药用植物的抗菌膜活性。

原始出处:

Dolatabadi S, Moghadam HN, Mahdavi-Ourtakand M. Evaluating the anti-biofilm and antibacterial effects of Juglans regia L. extracts against clinical isolates of Pseudomonas aeruginosa. Microb Pathog. 2018 Mar 29. pii: S0882-4010(17)31531-0. doi: 10.1016/j.micpath.2018.03.055.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084357, encodeId=1acd208435e7e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 18 11:00:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857602, encodeId=71c6185e602bc, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Oct 22 02:00:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061146, encodeId=7425206114614, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Feb 21 19:00:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302363, encodeId=138f30236373, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Apr 03 12:15:56 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2019-03-18 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084357, encodeId=1acd208435e7e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 18 11:00:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857602, encodeId=71c6185e602bc, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Oct 22 02:00:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061146, encodeId=7425206114614, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Feb 21 19:00:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302363, encodeId=138f30236373, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Apr 03 12:15:56 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084357, encodeId=1acd208435e7e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 18 11:00:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857602, encodeId=71c6185e602bc, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Oct 22 02:00:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061146, encodeId=7425206114614, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Feb 21 19:00:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302363, encodeId=138f30236373, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Apr 03 12:15:56 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084357, encodeId=1acd208435e7e, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 18 11:00:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857602, encodeId=71c6185e602bc, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Oct 22 02:00:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061146, encodeId=7425206114614, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Feb 21 19:00:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302363, encodeId=138f30236373, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Apr 03 12:15:56 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 1ddf0692m34(暂无匿称)

    学习了.长知识

    0